Rentschler Biopharma Restructures Global Operations, Focusing on Biologics
LAUPHEIM, Germany, Jan. 30, 2025 — Rentschler Biopharma SE, a leading global contract development and manufacturing organization (CDMO) for biopharmaceuticals, today announced a strategic realignment of its global operations. This long-term strategic shift involves Rentschler Biopharma withdrawing from cell and gene therapy, closing its Stevenage, UK facility, and concentrating on biologics1. This decision reflects the company’s response to evolving market dynamics and client needs, emphasizing sustainable growth and innovation.
Benedikt von Braunmühl, CEO of Rentschler Biopharma, stated, “As an innovation leader, we continuously assess approaches to best serve our clients and their patients. The cell and gene therapy market’s growth has been slower than anticipated, with industry demand falling short of expectations. Following a thorough strategic review, we’re focusing on areas with higher demand and sustainable value-creation potential. Biologics remain core to our operations, and we continue to explore other modalities, leveraging our expertise and proven track record of exceptional quality and service.” He added, “Our Stevenage team has shown exceptional dedication and performance, and I thank them for their contributions. We’re committed to supporting affected employees throughout this transition.”
Rentschler Biopharma has made substantial investments in recent years to bolster its global capabilities and support long-term growth. In 2024, the company announced its largest-ever investment at its Laupheim headquarters, enhancing production efficiency and site capabilities. Earlier that year, a new state-of-the-art production line in Milford, MA, became fully operational, featuring four new 2,000 L single-use bioreactors. This investment, the largest in Rentschler Biopharma’s 150+ year history, significantly expands the company’s capacity to meet the growing biopharmaceutical demand.
1 cell-culture based therapeutic protein formats
About Rentschler Biopharma SE
Rentschler Biopharma is a leading contract development and manufacturing organization (CDMO) exclusively focused on client projects. The company provides biopharmaceutical process development and manufacturing, along with consulting, project management, and regulatory support. Rentschler Biopharma’s high quality is demonstrated by its extensive experience and reputation as a client solutions partner. A robust quality management system, established operational excellence philosophy, and advanced technologies ensure product quality and productivity at every development and manufacturing stage. Rentschler Biopharma is a family-owned company with approximately 1,400 employees, headquartered in Laupheim, Germany, with operations in Milford, MA, USA. In 2024, the company joined the United Nations Global Compact, highlighting its commitment to sustainability. For more information, please visit . Follow Rentschler Biopharma on .
Contact: |
Rentschler Biopharma SE |
Dr. Latika Bhonsle-Deeng Head of Communications Phone: +49-7392-701-874 |
Media inquiries: |
MC Services AG |
Eva Bauer |
Phone: +49-89-210228-0 |
U.S. |
Laurie Doyle |
Phone: +1-339-832-0752 |
“`